NEW YORK (GenomeWeb News) – Neogenomics today reported a 73 percent uptick in first-quarter revenues year over year as the number of tests performed increased 75 percent.

Revenues for the three months ended March 31 totaled $15.2 million, up from $8.8 million a year ago. The number of tests performed during the quarter increased to 26,932 from 15,396 a year ago.

A net loss of $893,000, or $.02 per share, a year ago was turned into a profit of $603,000, or $.01 per share, in Q1 2012.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.